Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03998735 · ClinicalTrials.gov registry record · Phase 1
Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure
A Phase 1 study of Smokeless Tobacco, sponsored by Masonic Cancer Center, University of Minnesota.
- Active
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT03998735: Active Phase 1 study of Smokeless Tobacco, sponsored by Masonic Cancer Center, University of Minnesota.
NCT03998735 is a Phase 1 study of Smokeless Tobacco that is active but no longer recruiting, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 55 participants, below the 225-participant average among 3 other Smokeless Tobacco trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03998735, a Phase 1 study of Smokeless Tobacco, is active but no longer recruiting, sponsored by Masonic Cancer Center, University of Minnesota.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
Our goal in this study is to investigate the extent of endogenous nitrosation of nornicotine in smokeless tobacco users as a function of nornicotine content in smokeless products. This study will lead to an understanding of the endogenous formation of NNN from nornicotine in humans, and will also investigate the effect of the reduction of nornicotine content in smokeless tobacco on the extent of endogenous NNN formation. The knowledge gained in this study will lead to the development of recommendations for the regulation, or potentially elimination, of nornicotine in smokeless tobacco products in order to minimize exposure to NNN in the users of these products.
Primary Outcome
Presence of urinary \[pyridine-D4\]NNN (\[D4\]NNN)
Conditions Studied
Interventions
- DRUG Herbal Snuff (Smokeless Tobacco)
Study Locations (1)
Minnesota
- Masonic Cancer Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2021-10-19 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
What the registry record for NCT03998735 still lists
NCT03998735 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 225-participant average among 3 other Smokeless Tobacco trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Smokeless Tobacco appearing as the primary indexed condition, and to 1 intervention - of which Herbal Snuff (Smokeless Tobacco) is the first listed.
NCT03998735 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03998735 about?
NCT03998735 is a clinical study titled "Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure". Our goal in this study is to investigate the extent of endogenous nitrosation of nornicotine in smokeless tobacco users as a function of nornicotine content in smokeless products. This study will lead to an understanding of the endogenous formation of NNN from nornicotine in humans, and will also in...
What is the current status of trial NCT03998735?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2021-10-19. Estimated completion is 2026-08.
What conditions does trial NCT03998735 study?
This clinical trial studies the following conditions: Smokeless Tobacco.
What interventions are being tested in trial NCT03998735?
The interventions under investigation include: Herbal Snuff (Smokeless Tobacco) (DRUG).
Who is sponsoring clinical trial NCT03998735?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03998735 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smokeless Tobacco
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI